Report on operations 2015: Continued profitable growth

Fourth quarter:

  · Sales amounted to SEK 199 (137) million, corresponding to an increase of 45
percent in SEK. Net sales growth was 38 percent in local currency.
  · Operating income before depreciation and amortization (EBITDA) amounted to
SEK 81 (44) million, corresponding to a margin of 41 (32) percent.
  · Net income amounted to SEK 57 (28) million, which gave earnings per share of
SEK 2.63 (1.39).

Whole year 2015:

  · Sales amounted to SEK 722 (511) million, corresponding to an increase of 41
percent in SEK. Net sales growth was 28 percent in local currency.
  · Operating income before depreciation and amortization (EBITDA) amounted to
SEK 279 (167) million, corresponding to a margin of 39 (33) percent.
  · Net income amounted to SEK 183 (109) million, which gave earnings per share
of SEK 8.42 (5.46).

After the end of the year:

  · The Board proposes a dividend of SEK 2.40 (1.50) per share.
  · Decision to consolidate the Group’s time-lapse business to the subsidiary
Vitrolife A/S in Denmark during 2016.

Gothenburg, February 5, 2016
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on
February 5, 2016 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces
and markets medical devices for assisted reproduction. Work is also carried out
to enable the use and handling of stem cells for therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold in
almost 110 markets. The company is headquartered in Gothenburg, Sweden, and
there are also offices in USA, Australia, France, Italy, United Kingdom, China,
Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX
Stockholm, Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/